

doi: 10.14735/amcsnn2020424

# The prevalence and characteristics of epilepsy in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapy

Prevalence a charakteristika epilepsie u pacientů s relabující-remitující formou roztroušené sklerózy léčených imunomodulační terapií

## Abstract

**Aim:** The aim was to identify and describe patients with relapsing-remitting MS (RRMS) treated with a disease-modifying therapy who had a history of unprovoked seizure or epilepsy and to investigate the impact of epilepsy on the course and prognosis of MS. **Materials and methods:** Patients with RRMS treated with a disease-modifying therapy at a large MS centre of the university hospital by January 1, 2019 were included in this study. The annual relapse rate and Expanded Disability Status Scale (EDSS) before and after the first seizure were evaluated. **Results:** 17 patients (2.27%) with a history of unprovoked seizure or epilepsy were identified within the cohort of RRMS patients (N = 750). Active epilepsy, defined as the use of antiepileptic drugs or incidence of seizures within the last 5 years, was disclosed in 13 (73%) of them. Three patients had developed epilepsy before the first signs of MS. The mean annual relapse rates in patients with epilepsy before and after the first seizure were 0.12 and 0.5 (P = 0.1), resp. No significant difference was found in terms of EDSS worsening at 2 years before and after the first seizure (0.55 vs. 0.7; P = 0.38). The attack semiology and/or electroencephalogram recordings indicated a focal onset of seizures in 8 out of 17 patients (47%). **Conclusion:** The frequency of unprovoked seizure or epilepsy among RRMS patients in our cohort was 2.27%.

## Souhrn

**Cíl:** Cílem bylo vyhledat pacienty s relabující-remitující formou RS (RRMS) léčené imunomodulační terapií, kteří mají v anamnéze neprovokovaný epileptický záchvat, či se léčí s epilepsií, a zhodnotit vliv epilepsie na průběh a prognózu RS. **Soubor a metodika:** Do studie byli zařazeni pacienti s RRMS léčení imunomodulační léčbou a docházející do centra RS fakultní nemocnice k 1. lednu 2019. Byly hodnoceny roční míra relapsů a Expanded Disability Status Scale (EDSS) před a po prvním záchvatu. **Výsledky:** V kohortě pacientů s RRMS (n = 750) bylo nalezeno 17 pacientů (2,27 %) s historií neprovokovaných záchvatů nebo epilepsie. Aktivní epilepsie, definována užíváním antiepileptik či výskytem záchvatů v posledních 5 letech, byla zjištěna u 13 pacientů (73 %). Tři pacienti měli již diagnostikovanou epilepsii před prvními symptomy RS. Medián roční míry relapsů u pacientů s epilepsií byl 0,12 před prvním záchvatem a 0,5 po prvním záchvatu (p = 0,1). Nebyl nalezen signifikantní rozdíl mezi zhoršováním EDSS 2 roky před a 2 roky po prvním záchvatu (0,55 vs. 0,7; p = 0,38). Záchvat byl hodnocen jako fokální na základně klinické manifestace a/nebo EEG u 8 ze 17 pacientů (47 %). **Závěr:** Frekvence neprovokovaného epileptického záchvatu či epilepsie u pacientů s RRMS byla v naší kohortě 2,27 %.

The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

J. Kolčava, J. Kočica, P. Štourač,  
J. Bednařík

Department of Neurology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic



MUDr. Jan Kočica  
Department of Neurology  
Faculty of Medicine  
Masaryk University  
and University Hospital  
Jihlavská 340/20  
625 00 Brno  
e-mail: kocica.jan@fnbrno.cz

Accepted for review: 8. 1. 2020  
Accepted for print: 16. 6. 2020

## Key words

multiple sclerosis – epilepsy – seizures – prevalence

## Klíčová slova

roztroušená skleróza – epilepsie – záchvaty – prevalence

## Introduction

Multiple sclerosis is a chronic inflammatory and degenerative disease of the CNS. It is the leading cause of neurologic disability (not arising out of trauma) in young adults and is characterized by focal white matter lesions; however, both deep and cortical grey matter are also involved [1,2]. Patients with MS and epilepsy had a higher risk of mortality compared with those without [3]. A recent study derived from the Swedish MS registry (N = 14,545) revealed a cumulative incidence of epilepsy of 3.5% in patients with MS and 1.4% in controls. Patients with relapsing-remitting MS (RRMS) had a cumulative incidence of epilepsy of 2.2%, whereas in patients with the progressive disease this reached 5.5% [4].

The frequency of active epilepsy among MS patients in Nordland (county in Norway) was 3.2%, approximately 4.5 times higher than in the general Norwegian population. The RRMS patients with active epilepsy had more likely converted to secondary progressive MS than the patients without active epilepsy [5].

The cause of such an increased occurrence of epilepsy among patients with MS

is unknown, but it is reasonable to assume an epileptogenic role played by cortical lesions [6,7]. The aim of our retrospective cohort study was to identify and describe patients with RRMS treated with a disease-modifying therapy who had a history of unprovoked seizure or epilepsy and to assess the impact of epilepsy on the course of MS in terms of the annual relapse rate (ARR) and Expanded Disability Status Scale (EDSS) at 2 years before and after the first seizure.

## Materials and Methods

A cohort of 750 patients (504 women and 246 men) currently suffering from RRMS according to the McDonald diagnostic criteria, 2017 [8], seen at the MS centre of the large university hospital in the region of 612,000 inhabitants in the period leading up to January 1, 2019 were screened. Their case histories based on the electronic patient ledger were scrutinized to identify seizures. Epilepsy was classified as focal or generalized, based on recorded seizure semiology and EEG findings. The age, sex and treatment for MS and epilepsy were noted. The values of ARR and EDSS were analysed

over the periods lasting for 2 years – both before and after the first seizure, to establish whether the seizures were directly involved in the severity of MS. The ANOVA (Analysis of Variance) test was used for the correlation of ARR and EDSS in our cohort. Patients presenting with seizures before MS diagnosis were excluded from the ARR or EDSS analysis.

## Results

Among 750 patients with RRMS treated with a disease-modifying therapy, 17 patients (age  $41.2 \pm 10.4$  years) with a history of seizure (prevalence 2.27%) were identified, 12 of them were women (age  $43.6 \pm 10.5$  years) and 5 men ( $35.6 \pm 10.5$  years). Three patients had epilepsy before the first symptoms of MS (18%) (Fig. 1). The mean ARR in patients with epilepsy at 2 years before and after the first seizure were 0.12 and 0.5 (P = 0.1), resp. The mean values of EDSS at 2 years before and after the first seizure were 2.9 and 4.15, resp. The EDSS at the first seizure was 3.45 in the cohort (N = 10). No significant difference was found in terms of EDSS worsening at 2 years before and after the first seizure (0.55 vs. 0.7; P = 0.38).

Tab. 1. Demographic data of relapsing-remitting MS patients with epilepsy.

Sex	Age	MS dg. (age)	EDSS at 1. seizure	EDSS 2019	1. seizure (age)	seizure (type)	normal EEG	AED	DMT at the onset of EP	DMT 2019
F	63	53	0	4.5	54	focal	yes	LEV, VPA	none	GA
F	43	34	1.5	4	43	focal	yes	no	none	NAT
M	32	26	2.5	2.5	27	generalized	no	no	IFN	IFN
F	35	24	5.0	5.5	33	generalized	no	LEV	NAT	NAT
F	46	20	2.5	3.5	36	focal	no	VPA	DAC	FNG
M	45	31	5.5	6.0	44	generalized	no	VPA	FNG	OCR
F	38	17	3.0	3.0	37	generalized	yes	LTG	IFN	IFN
F	27	20	0	3.0	12	generalized	yes	no	none	DMF
F	60	37	5.0	5.5	57	focal	yes	LTV, VPA	IFN	GA
F	37	34	0	6.0	32	generalized	yes	no	none	DMF
M	36	13	2.0	4.0	28	focal	yes	LTG	GA	GA
F	49	46	2	3.0	46	generalized	yes	no	none	DMF
F	30	23	2.0	2.5	25	focal	no	no	IFN	NAT
M	31	23	1.5	4.5	25	generalized	yes	no	IFN	FNG
M	34	30	1.0	1.5	30	generalized	yes	no	none	TRF
F	38	17	0	4.5	15	generalized	yes	no	none	NAT
F	57	22	6	6.5	53	generalized	no	LTG	GA	GA

AED – antiepileptic drug; DAC – daclizumab; DMF – dimethyl fumarate; DMT – disease-modifying therapy; EDSS – Expanded Disability Status Scale; EEG – electroencephalogram; EP – epilepsy; F – female; FNG – fingolimod; GA – glatiramer acetate; IFN – interferon beta; LEV – levetiracetam; LTG – lamotrigine; M – male; NAT – natalizumab; OCR – ocrelizumab; TRF – teriflunomide; VPA – valproate

The mean age at which the first symptoms of MS appeared was  $27.6 \pm 10.3$  years and the mean age at which the first seizure occurred was  $35.1 \pm 12.6$  years. At least one EEG was recorded for all patients with MS and epilepsy. Epileptiform discharges appeared in six patients (35%). The demographic and clinical data of the cohort were analysed (Tab. 1).

Eight out of 14 patients (57%) exhibited new T2-lesions on brain MRI findings after the first seizure. However, detailed analysis of MRI finding was not possible because of the retrospectivity of this study. The determination of the number or extent of cortical lesions was not possible due to a change in the MRI protocol over the follow-up and inability to detect reliable cortical lesions in older findings.

## Discussion

The frequency of unprovoked seizure or epilepsy among RRMS patients in this cohort was 2.27%, which is higher than in the general population [9]. The frequency of focal epilepsy was 47%. There remains a possibility that patients with generalized seizure and normal EEG had a focal onset of seizure with a focal-to-bilateral tonic-clonic seizure; the frequency of focal epilepsy may, therefore, be underestimated. These findings are in agreement with international reports. There was found a non-significant trend towards an increase in ARR in patients with epilepsy at 2 years before and after the first seizure. No significant difference in the mean EDSS was found 2 years before and after the first seizure.

The accuracy of the diagnosis of epilepsy may, however, give cause for concern, especially among MS patients in whom there may be a range of paroxysmal symptoms such as muscle cramps, dystonia and other involuntary movements.

Furthermore, the high frequency of focal epilepsy disclosed supports the proposition that localized MS pathology lies behind comorbid epilepsy. MS patients with epilepsy have a higher prevalence of cortical lesions than patients without seizures in their case histories [6,10].

Coincidental occurrence of epilepsy and MS could account for some of the cases. It is also possible that several of these patients suffer from idiopathic epilepsy, clinically triggered in a nonspecific way by the cerebral metabolic disturbance resulting from about MS. It has been argued that




Fig. 1. Latency from the first symptom of MS to the first seizure.

Obr. 1. Latence od prvního symptomu RS k prvnímu záchvatu.

acute symptomatic seizures are caused by new MS lesions and that chronic epilepsy is unrelated to new attacks of the disease, but rather to the epileptogenic effect of chronic cortical plaques. Cortical lesions are also an independent predictor of the conversion from a clinically isolated syndrome to MS [11].

Neuroinflammation plays an important role in the pathogenesis of MS but is also commonly activated in epileptogenic brain regions in humans and is clearly involved in animal models of epilepsy [12]. Thus, neuroinflammation could serve as a possible link from MS to epilepsy and explain the development of seizures in a subset of MS patients.

While MS lesions in the white matter are readily visualized by MRI, conventional MRI techniques are of low sensitivity in the detection of gray-matter MS pathology, a drawback that hinders accurate assessment of the total lesion burden. Newer MRI sequences such as double inversion recovery and phase-sensitive inversion recovery are 1.5–5 times more sensitive than conventional MRI sequences in the detection of cortical lesions [13].

The findings could have important implications for clinicians since there exists a need to be aware of the risk of epilepsy in people with MS. The clinician may, in particular, wish to consider whether the patient displays any other risk factors for epilepsy, such as medication and/or alcohol abuse, which might potentially exacerbate the risk. Because of the possibility of new seizures and status epilepticus, attention has been drawn to the importance of early use of antiepileptic drugs in MS patients with epilepsy. Clinicians should also be aware of the hypothetical proconvulsive properties of interferon-beta arising out of metabolic inter-

ference with antiepileptic drugs or caused by direct neurotoxic effects [14].

Some progression on MRI was found after the first seizure in 57% patients. However, detailed analysis of MRI findings was not possible because of the retrospectivity of the study. Due to a change in the MRI protocol over the follow-up, determination of the number or extent of cortical lesions was not possible. The retrospective study has its limits, but it is a good starting point for planning a prospective multicentre study.

## Limitations

This is a single centre cohort retrospective study. It was not possible to use the ILAE classification 2017 accurately due to the retrospectivity of the study. No recent information about the accurate prevalence of epilepsy in our region was found. A small cohort of patients exhibits epilepsy in our study. Detailed analysis of MRI findings was not possible. It was not possible to compare patients with and without epilepsy in the framework of/connection with demographic data.

## Ethics approval

The research was approved by the local ethics committees (FN Brno; 04-170419/EK;17.4.2019).

## Acknowledgment

Supported by the Ministry of Health of the Czech Republic. Grant ref.: MH CZ – DRO, FNBr, 65269705. Tony Long (Svinošice) helped work up the English.

## Conflict of interest

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

## References

1. Geurts JJ, Bö L, Pouwels PJ et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. *AJNR Am J Neuroradiol* 2005; 26(3): 572–577.

2. Dagiasi I, Vall V, Kumlien E et al. Treatment of epilepsy in multiple sclerosis. *Seizure* 2018; 58: 47–51. doi: 10.1016/j.seizure.2018.04.001.
3. Chou JJ, Kuo CF, Tanasescu R et al. Epilepsy and associated mortality in patients with multiple sclerosis. *Eur J Neurol* 2019; 26(2): 342–e23. doi: 10.1111/ene.13821.
4. Burman J, Zelano J. Epilepsy in multiple sclerosis: a nationwide population-based register study. *Neurology* 2017; 89(24): 2462–2468. doi: 10.1212/WNL.00000000000004740.
5. Benjaminsen E, Myhr KM, Alstadhaug KB. The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway. *Seizure* 2017; 52: 131–135. doi: 10.1016/j.seizure.2017.09.022.
6. Gasparini S, Ferlazzo E, Ascoli M et al. Epilepsy Study Group of the Italian Neurological Society: risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis. *Neurol Sci* 2017; 38(3): 399–406. doi: 10.1007/s10072-016-2803-7.
7. Martinez-Lapiscina EH, Ayuso T, Lacruz F et al. Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis. *Acta Neurol Scand* 2013; 128: 24–31. doi: 10.1111/ane.12064.
8. Thompson A, Banwell B, Barkoff F. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald Criteria. *Lancet Neurol* 2018; 17(2): 162–173. doi: 10.1016/S1474-4422(17)30470-2.
14. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. *Neurology* 2017; 88(3): 296–303. doi: 10.1212/WNL.0000000000000509.
10. Calabrese M, Grossi P, Favaretto A et al. Cortical pathology in multiple sclerosis patients with epilepsy: a 3-year longitudinal study. *J Neurol Neurosurg Psychiatry* 2012; 83: 49–54. doi: 10.1136/jnnp-2011-300414.
11. Filippi M, Rocca MA, Calabrese M et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. *Neurology* 2010; 75: 1988–1994. doi: 10.1212/WNL.0b013e3181ff96f6.
12. Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. *Nat Rev Neurol* 2019; 15(8): 459–472. doi: 10.1038/s41582-019-0217-x.
13. Nelson F, Poonawalla AH, Hou P et al. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. *AJNR Am J Neuroradiol* 2007; 28: 1645–1649.
14. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. *Neurology* 1999; 53: 1622–1627.

## Soutěž o nejlepší práci publikovanou v časopise Česká a slovenská neurologie a neurochirurgie

V roce 2020, stejně jako v předchozích letech, probíhá soutěž o nejlepší článek v časopise *Cesk Slov Neurol N*.  
Zařazený budou práce otištěné v číslech 2020/1–6.

Předem děkujeme všem autorům za zaslání příspěvků.